Indivior PLC (NASDAQ:INDV) Receives Average Recommendation of “Moderate Buy” from Analysts

Indivior PLC (NASDAQ:INDV) has been assigned an average rating of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $40.2857.

INDV has been the subject of several recent research reports. Weiss Ratings upgraded Indivior from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, June 23rd. Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 29th. Finally, Barclays initiated coverage on Indivior in a report on Thursday, June 18th. They set an “overweight” rating and a $46.00 target price for the company.

Insider Buying and Selling

In related news, CFO Ryan Preblick sold 36,000 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $37.70, for a total transaction of $1,357,200.00. Following the completion of the transaction, the chief financial officer owned 284,751 shares of the company’s stock, valued at approximately $10,735,112.70. The trade was a 11.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.74% of the company’s stock.

Hedge Funds Weigh In On Indivior

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd raised its stake in shares of Indivior by 72.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock worth $39,000 after acquiring an additional 460 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its stake in shares of Indivior by 3.4% in the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 21,200 shares of the company’s stock valued at $761,000 after purchasing an additional 700 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Indivior by 17.8% during the 4th quarter. Blue Trust Inc. now owns 4,859 shares of the company’s stock valued at $176,000 after purchasing an additional 733 shares during the last quarter. Harbor Capital Advisors Inc. raised its position in Indivior by 309.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after purchasing an additional 781 shares during the period. Finally, Salomon & Ludwin LLC purchased a new position in Indivior in the 4th quarter worth $30,000. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Indivior Stock Up 1.8%

INDV traded up $0.73 during trading on Tuesday, hitting $40.73. 253,345 shares of the company’s stock were exchanged, compared to its average volume of 2,221,024. Indivior has a fifty-two week low of $14.93 and a fifty-two week high of $42.81. The stock has a market cap of $4.97 billion, a P/E ratio of 20.89 and a beta of 0.86. The business’s 50 day moving average is $37.98 and its two-hundred day moving average is $34.87.

Indivior (NASDAQ:INDV) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.96 earnings per share for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. The company had revenue of $317.00 million during the quarter. On average, sell-side analysts forecast that Indivior will post 4.05 earnings per share for the current year.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.